June 19, 2008 |
Amgen Inc. won an advisory panel's support for the use of its drug Enbrel in children with moderate to severe psoriasis. The outside experts voted, 8 to 5, to recommend that the Food and Drug Administration expand Enbrel's approved uses to children with the sometime debilitating skin disorder, after testimony weighing the drug's benefits against its potential for cancer and other side effects. The FDA isn't required to follow the panel's lead, though it usually does.
March 7, 2008 |
Amgen Inc. will pay Kyowa Hakko Kogyo Co. $100 million initially and as much as $420 million tied to the development of an experimental medicine for inflammation and cancer, the companies said. Kyowa Hakko is the Tokyo-based drug unit of Kirin Holdings Co. The deal gives Thousand Oaks-based Amgen a potential medication that could join its anti-inflammatory medicine Enbrel. Shares fell $1.01 to $44.24.
December 14, 2001 |
Amgen Inc., the world's largest biotechnology company, is in talks to buy rival Immunex Corp. for about $17 billion in cash and stock, people familiar with the negotiations said Thursday. The deal, if completed, would put some of the most promising biotechnology drugs today under one roof and would combine Amgen's manufacturing capability with Immunex's scientific expertise in the growing field of anti-inflammatory drugs.
April 24, 2013 |
Shares of biotech giant Amgen Inc. slumped Wednesday as investors reacted to weaker-than-expected first-quarter sales. Shares of the Thousand Oaks company dropped $6.41, or nearly 6%, to $106.35 in trading Wednesday. The company's stock had posted impressive gains until this week, up 65% in the last year. Amgen reported first-quarter results after the markets closed Tuesday. Its net income rose 21% to $1.4 billion, or $1.88 a share, from $1.2 billion, or $1.48 a share, a year earlier.
January 27, 2009 |
Amgen Inc.'s profit grew 15% in the fourth quarter, mostly as a result of lower expenses, the company said Monday. Amgen's profit rose to $961 million, or 91 cents per share, compared with $835 million, or 76 cents, a year earlier. Revenue was essentially unchanged at $3.75 billion, as sales rose for its anti-infection drug Neulasta and rheumatoid arthritis treatment Enbrel while sales of its anemia drugs declined further. Excluding one-time costs, Amgen said it earned $1.12 billion in the quarter, or $1.06 per share, up from $1.09 billion, or $1 per share, a year earlier.
March 4, 2004 |
Genentech Inc. of South San Francisco disclosed in a regulatory filing that it was unlikely to produce Enbrel, an arthritis drug, for biotech rival Amgen Inc. on schedule. Enbrel, with sales of $1.3 billion in 2003, is a key growth driver for Thousand Oaks-based Amgen but a shortage of production capacity has hurt sales in the past.